Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

(AHAC)

(AHAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp. Globe NewsWire - Thu Aug 26, 2021

DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...

AHAC : 10.96 (+7.98%)
Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte Globe NewsWire - Tue Aug 24, 2021

NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders...

AHAC : 10.96 (+7.98%)
DMTK : 0.0940 (-11.32%)
Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels Globe NewsWire - Thu Aug 19, 2021

DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced...

AHAC : 10.96 (+7.98%)
DMTK : 0.0940 (-11.32%)
Humacyte Announces Addition of Chief Commercial Officer and Integration of Commercial-Scale Manufacturing into Clinical Trial Programs Globe NewsWire - Tue Aug 17, 2021

DURHAM, N.C., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...

AHAC : 10.96 (+7.98%)
DMTK : 0.0940 (-11.32%)
Alpha Healthcare and Humacyte Announce Nominees for Election to Post-Merger Public Company Board of Directors Globe NewsWire - Fri Aug 13, 2021

NEW YORK and DURHAM, N.C., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced the nominees who will...

AHAC : 10.96 (+7.98%)
DMTK : 0.0940 (-11.32%)
Humacyte Announces Publication of In Vivo Data on Biovascular Pancreas Transplantation for the Treatment of Type 1 Diabetes Globe NewsWire - Wed Aug 11, 2021

DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced...

AHAC : 10.96 (+7.98%)
DMTK : 0.0940 (-11.32%)
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination Globe NewsWire - Wed Aug 4, 2021

NEW YORK and DURHAM, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that it has filed a...

AHAC : 10.96 (+7.98%)
DMTK : 0.0940 (-11.32%)
Humacyte Presents Potential of Functional Lung Engineering at Janelia R3 – Replace, Repair, Regenerate Planning Workshop Globe NewsWire - Thu Jul 22, 2021

DURHAM, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...

AHAC : 10.96 (+7.98%)
DMTK : 0.0940 (-11.32%)
UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care Globe NewsWire - Fri Jun 11, 2021

DURHAM, N.C., June 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announces...

AHAC : 10.96 (+7.98%)
DMTK : 0.0940 (-11.32%)
Humacyte to Participate in Fireside Chat at Cowen 6th Annual FutureHealth Conference Globe NewsWire - Thu Jun 10, 2021

DURHAM, N.C., June 10, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...

AHAC : 10.96 (+7.98%)
DMTK : 0.0940 (-11.32%)

Barchart Exclusives

This Penny Stock Just Surged 380% on a Mega Deal. Is It a Buy, Sell, or Hold? Barchart - 25 minutes ago
LeddarTech is a beaten-down penny stock that is on the move after securing a licensing deal with a semiconductor giant. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot